Harnessing real-world data to improve healthcare management

Quality of care

Drug use

Costs of illness

  • News

    PELyon has adopted home based working for all of its employees since March, without affecting our activities. We will continue to favor this way of working, in order to follow government recommendations.

  • News

    PELyon is proud to be part of the new European Network to Advance Best Practices & Technologies on Medication Adherence (ENABLE). It has just been funded by the European Union’s Cooperation in Science and Technology (COST). Awareness of healthcare professionals on the availability and implementation of adherence enhancing technology is limited and there is a lack of collaboration between stakeholders. This affects not only patients and healthcare professionals, but also manufacturers of technology (mostly SMEs) in their innovation capacity and competitiveness.

    To address these challenges, ENABLE aims (amongst others):

    1. to establish multidisciplinary medication adherence expertise centers in each country,

    2. review novel adherence enhancing technologies,

    3. organize training schools,

    4. offer short-term fellowships for early career investigators,

    5. organize conferences.


  • News

    PELyon is proud to announce it joins the AFCRO (French Association of CROs)

    AFCROs logo


  • Manon Belhassen et Eric Van Gense


    Interview by the Healthcare Data Institute
    This month, Manon Belhassen and Eric Van Ganse were interviewed by the Healthcare Data Institute regarding health data valorisation.
Presentation of PELyon
PELyon conducts a broad range of research projects, with emphasis on pharmacoepidemiological studies, burden/cost of illness, adherence and Comparative Effectiveness Research.

PELyon consists of Medical Doctors, Epidemiologists, Project Managers, Data Managers and Statisticians, who combine their skills and experience to address current health-related issues.

PELyon aims at helping decision-makers (health authorities, biomedical industries, and healthcare settings) by offering tools that will enable them to choose between different therapeutic strategies or public health programmes.